Keep Your Finger on the Pulse: Q4 2024 PulsePoint Recap Newsletter
In Q4, Shockwave IVL made big waves at some of our biggest U.S. conferences, revealing eagerly anticipated products and clinical trial milestones.
At this year’s TCT, we unveiled Shockwave Javelin to our U.S. customers, our first Peripheral IVL catheter designed for balloon-uncrossable lesions. We were also thrilled that EMPOWER CAD — a landmark Coronary IVL study with all female patients — completed enrollment, with the 400th and final patient enrolled in a live case at TCT by Dr. Margaret McEntegart.
Finally, at VIVA, FORWARD PAD data showcased the first-ever PAD outcomes with Shockwave Javelin while the 30-Day DISRUPT BTK II outcomes showed that patients treated with Peripheral IVL experienced significant quality of life and wound healing improvements with minimal adverse events. Read the latest PulsePoint newsletter to learn more about these and other momentum-building Q4 moments.
Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.
Shockwave Reducer: Investigational Use Only in the U.S. and Canada. Available in select international geographies. Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events.